Home Bratislava Medical Journal 2019 Bratislava Medical Journal Vol.120, No.1, p.70–77, 2019

Journal info


 


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345
 

Aims and Scope
Editorial Info
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.120, No.1, p.70–77, 2019

Title: Is there a new pathway relationship between melatonin and FEZ1 in experimental rat model of Alzheimer’s disease?
Author: M. Demir, U. Yilmaz, C. Colak, Y. Cigremis, F. Ozyalin, I. Tekedereli, S. Sandal

Abstract: Alzheimer’s disease (AD) is a progressive neurodegenerative disease. This study was performed to determine the possible relationship between melatonin, which is known to play a role in the neuro-protective mechanism in AD, and fasciculation and elongation protein zeta 1 (FEZ1). Thirty male rats were included and separated into 3 groups (n = 10) as vehicle (artificial cerebrospinal fluid), streptozotocin (STZ) and STZ+melatonin (MLT). Two intracerebroventricular (icv) injections of 3 mg/kg STZ were made 48 hours apart. MLT injections were implemented for 14 days (ip; 10mg/kg/day). The Morris Water Maze (MWM) test was performed and rats were sacrificed to assess FEZ1 gene expression and protein levels from the hippocampus tissues and serum levels of noradrenaline (NA), dopamine and serotonin were determined from the blood samples. It was determined that the FEZ1/β-actin protein ratio in the STZ group was significantly higher than that of the Vehicle group (p < 0.05) and in the MLT‑administered group, the protein levels were decreased to the levels observed in the Vehicle group. Serum NA levels of STZ and STZ+MLT groups were found to be lower than those in the Vehicle group, while no difference was found regarding dopamine and serotonin levels.
These findings show that reversal of increased FEZ1 levels in AD-induced rats with melatonin administration is the evidence of the effect of melatonin through FEZ1 in AD (Tab. 2, Fig. 5, Ref. 67).

Keywords: FEZ1, Alzheimer’s disease, melatonin, rat, microtubules, mitochondria
Published online: 22-Jan-2019
Year: 2019, Volume: 120, Issue: 1 Page From: 70, Page To: 77
doi:10.4149/BLL_2019_011


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.